Engineered immune cells take on tough lymphoma in early trial
Disease control
Recruiting now
This early-phase study is testing a personalized treatment for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard therapy. The approach involves taking a patient's own immune cells, genetically modifying them to recognize and attack…
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated May 04, 2026 16:31 UTC